| Market Capitalization (Millions $) |
972 |
| Shares
Outstanding (Millions) |
33 |
| Employees |
337 |
| Revenues (TTM) (Millions $) |
498 |
| Net Income (TTM) (Millions $) |
44 |
| Cash Flow (TTM) (Millions $) |
-113 |
| Capital Exp. (TTM) (Millions $) |
2 |
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc is a publicly traded specialty pharmaceutical company based in Stoughton, Massachusetts. It was founded in 2002 by Michael Heffernan, who is the current CEO, and Joseph Ciaffoni, the current COO.
The company specializes in the development and commercialization of innovative treatments for chronic pain and other conditions. They work to address unmet medical needs by developing new treatments that are safer, more effective, and more accessible than the current standard of care.
One of Collegium's most successful products is Xtampza ER, an extended-release opioid medication for the treatment of chronic pain. Xtampza ER was approved by the FDA in 2016 and is designed to be harder to abuse than other opioids. It is also formulated to be tamper-resistant, which reduces the risk of addiction and overdose.
Collegium also offers an innovative drug delivery technology platform called DETERx. This technology allows medication to be released slowly over time, which helps to reduce the risk of abuse and addiction. DETERx is used in Xtampza ER and other Collegium products.
The company has a strong research and development pipeline, with several products in various stages of development. In addition to chronic pain, they are also exploring treatments for other conditions such as neuropathic pain and opioid use disorder.
Collegium is committed to patient-centered care and works to ensure that their products are safe, effective, and accessible to those who need them. They have a team of experienced professionals and a strong corporate culture that focuses on innovation, collaboration, and excellence.
Overall, Collegium Pharmaceutical Inc is a leading specialty pharmaceutical company that is dedicated to improving the lives of patients with chronic pain and other conditions. Their innovative products and drug delivery technologies are helping to reduce the risk of addiction and overdose, while providing effective relief to those who need it most.
Company Address: 100 Technology Center Drive Stoughton 2072 MA
Company Phone Number: 713-3699 Stock Exchange / Ticker: NASDAQ COLL
|
12.16% 
67.52 %